Relevance of OncoVI three-class assessment: MTB selected expert reassessment to "Assess somatic small-variant oncogenicity"
- Use case
- Assess somatic small-variant oncogenicity
- Assessed by
- OncoVI three-class assessment: MTB selected expert reassessment
- Relevance
- Proxy evidence
- Endpoint
- Oncogenicity category agreement, sensitivity and reported subgroup performance
Assesses variant classification within the named reference; reference independence and transfer are bounded.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
15 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations1 values
| Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Constraints2 values
| Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Endpoint Oncogenicity category agreement, sensitivity and reported subgroup performance Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Claimed field links:assessed_by:uc-clinical-20260930-oncovi-expert-protocol Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Limitations3 values
| Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Pinned records10 values
| Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Rationale Assesses variant classification within the named reference; reference independence and transfer are bounded. Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Reason Add independently checked primary-source protocol evidence from the 17-use-case coverage audit; retain narrower endpoint and transfer limitations. Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Relevance proxy Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Revision 1 Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6 Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Original source · 2026 final full text in Europe PMC XML
Technical metadata and extraction receipts
Stable ID: use-case-mapping-20260930-344-401bec55db2f
- field
- links:assessed_by:uc-clinical-20260930-oncovi-expert-protocol
- value
- uc-clinical-20260930-oncovi-expert-protocol
- relevance
- proxy
- endpoint
- Oncogenicity category agreement, sensitivity and reported subgroup performance
- rationale
- Assesses variant classification within the named reference; reference independence and transfer are bounded.
- constraints
- A posteriori disagreement-enriched sample; same three experts and same reference resources; blinded to implementation, not independent resource adjudication.; Historical MTB 34% agreement with expert review compares functional-impact and oncogenicity labels; OncoVI 22% is against the old MTB labels, while 80% is against expert reassessment. Distinct metrics and references must not be pooled.
- limitations
- Not a treatment-selection benchmark.; No human domain review of this intake; reference overlap and prospective workload remain unresolved.; Abstract/body accuracy discrepancies retained.
- revision
- 1
- reason
- Add independently checked primary-source protocol evidence from the 17-use-case coverage audit; retain narrower endpoint and transfer limitations.
- citation locators
- source id: uc-clinical-20260930-source-oncovi; locator: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6
- source locator
- uc-clinical-20260930-source-oncovi: Results; Figures 2–4; ClinVar assessment; subgroup values referenced to Supplemental Table S6
- review
- method: automated-source-review; reviewer: codex; reviewer note: Codex source curation, independent worker cross-review and root integration review; reviewed at: 2026-09-30T21:54:30.217Z; note: Source-backed literature curation with independent automated transcription and scope checks. No new model execution, independent experimental replication, qualified human scientific review or clinical validation.
- reviewed evaluations
- uc-clinical-20260930-oncovi-expert-evaluation; uc-clinical-20260930-oncovi-prior-mtb-expert-evaluation
- pins
- record id: uc-clinical-20260930-oncovi-expert-evaluation; fields: status; links; attributes.origin; attributes.comparison; sha256: 44691a2f0ce6b074049dfa3d9a9d4b55ddf36f32645308624609167ede976b16; record id: uc-clinical-20260930-oncovi-expert-expert-concordance; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 84f714009c637f1e22038b2baa6a5c8e90f520536b51658b0d5c0ec6b2b914ae; record id: uc-clinical-20260930-oncovi-expert-prior-mtb-concordance; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: f3cdde2b0ade891bda340026be2c9d88f5415ba4c3ceb981cd873b5782079ef2; record id: uc-clinical-20260930-oncovi-expert-protocol; fields: status; name; description; facets; source_ids; links; attributes; sha256: d20ac49b35e34096d0649d5a3ea7df5815e5f769f0d152e7a408346a32279508; record id: uc-clinical-20260930-oncovi-expert-score-correlation; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 738e1a783b715aa04299d24f6483a2db63b4285ce7eb43142aafde65e3cb8d60; record id: uc-clinical-20260930-oncovi-prior-mtb-expert-agreement; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 5ba63305e7453c599d9c4be11f1fb138e8d560c4c75519e9b2c3691737847560; record id: uc-clinical-20260930-oncovi-prior-mtb-expert-concordant-count; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 815e31a0bf43049faafeb05b6f6b2126b0e426f8ea8bd06ad1ef38aa9f4552a5; record id: uc-clinical-20260930-oncovi-prior-mtb-expert-evaluation; fields: status; links; attributes.origin; attributes.comparison; sha256: e8cc277ba3108eb2ba80119f719a03c800de43e253639ee5909162d1f0dff791; record id: uc-clinical-20260930-source-oncovi; fields: status; attributes.artifact_sha256; sha256: dad6938e856ad8716c429176c36416ccfc5fb88e76d0e9084c804096a1673d0f; record id: use-case-somatic-small-variant-oncogenicity; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 8ccdc2d3923da8c5aa497bf2a0bd40ccafb89fa8b2f04819228dc52657155359